Halozyme Therapeutics HALO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Halozyme Therapeutics (HALO) Core Market Data and Business Metrics
Latest Closing Price
$61.87Price-Earnings Ratio
18.04Total Outstanding Shares
123.53 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
12390 El Camino Real, San Diego, CA, 92130
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,455,005 Shares | 6.92 | 3/14/2025 | 10,069,735 Shares |
| 1,365,287 Shares | 7.14 | 2/28/2025 | 9,748,013 Shares |
| 977,109 Shares | 9.44 | 2/14/2025 | 9,221,430 Shares |
| 1,072,280 Shares | 8.45 | 1/31/2025 | 9,055,762 Shares |
| 1,757,468 Shares | 5.35 | 1/15/2025 | 9,405,294 Shares |
| 1,532,701 Shares | 6.2 | 12/31/2024 | 9,504,876 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-218.86 Million |
| Net Cash Flow | $-2.52 Million |
| Net Cash Flow From Financing Activities | $-218.86 Million |
| Net Cash Flow, Continuing | $-2.52 Million |
| Net Cash Flow From Operating Activities, Continuing | $479.06 Million |
| Net Cash Flow From Investing Activities | $-262.72 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $3.43 |
| Cost Of Revenue | $159.42 Million |
| Diluted Average Shares | $129.42 Million |
| Operating Expenses | $304.43 Million |
| Benefits Costs and Expenses | $458.19 Million |
| Net Income/Loss | $444.09 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $457.20 Million |
| Comprehensive Income/Loss Attributable To Parent | $457.20 Million |
| Comprehensive Income/Loss | $457.20 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $978.14 Million |
| Liabilities | $1.70 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Current Assets | $907.16 Million |
| Other Non-current Liabilities | $54.76 Million |
| Inventory | $141.86 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||